Related Experiment Video

Updated: Aug 15, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 29, 2010

Somatostatin and cancer: applying endocrinology to oncology

Adda Grimberg1

  • 1Division od Pediatric Endocrinology, The Children's Hospital of Philadelphia, Philadephia, PA 19104-4318, USA. grimberg@email.chop.edu

Cancer Biology & Therapy
|August 25, 2004
PubMed

Insights

Somatostatin analogs, used for hormone-secreting tumors, show potential in treating nonendocrine malignancies like gastric cancer. These analogs target somatostatin receptors (SSTR), inhibiting tumor growth and inducing apoptosis.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Somatostatin is a peptide hormone regulating growth hormone, thyrotropin, insulin, and gut hormones via somatostatin receptors (SSTR).
  • Somatostatin analogs (octreotide, lanreotide) are established treatments for hormone-secreting tumors.
  • Emerging research explores somatostatin analogs for nonendocrine malignancies.

Discussion:

  • Hu et al. observed reduced SSTR3 expression in gastric adenocarcinomas correlating with differentiation.
  • Octreotide demonstrated in vitro efficacy, inhibiting growth and inducing apoptosis in SSTR3-expressing gastric cancer cells.
  • Potential therapeutic mechanisms involve endocrine actions, autocrine/paracrine effects, and SSTR-mediated signaling.

Key Insights:

  • Somatostatin receptor 3 (SSTR3) expression decreases with gastric adenocarcinoma progression.
  • Octreotide exhibits anti-tumor effects on SSTR3-positive gastric cancer cells.
  • Somatostatin analogs offer a potential therapeutic strategy for gastric cancer.

Outlook:

  • Further investigation into SSTR-mediated signaling pathways in nonendocrine tumors is warranted.
  • Clinical trials evaluating somatostatin analogs for gastric and other nonendocrine malignancies are anticipated.
  • SSTR-targeted therapies may represent a novel approach in cancer treatment.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior09:44

Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior

Published on: June 13, 2016

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...